西安交通大学学报(医学版)2024,Vol.45Issue(5) :695-704.DOI:10.7652/jdyxb202405001

抗幽门螺杆菌感染的研究进展

Advancements in studies on combatting Helicobacter pylori infection

黄婷婷 曹蕾 曹永孝
西安交通大学学报(医学版)2024,Vol.45Issue(5) :695-704.DOI:10.7652/jdyxb202405001

抗幽门螺杆菌感染的研究进展

Advancements in studies on combatting Helicobacter pylori infection

黄婷婷 1曹蕾 2曹永孝1
扫码查看

作者信息

  • 1. 西安交通大学医学部基础医学院药理系,陕西西安 710061
  • 2. 西安交通大学第二附属医院精准医学研究所,陕西西安 710004
  • 折叠

摘要

幽门螺杆菌(Hp)是胃炎、消化性溃疡病原菌,其感染遍及全球,感染率居高不下.抗菌药在胃的酸性环境中效果差,因而需同时针对细菌和胃酸进行治疗.奥美拉唑和阿莫西林曾是经典的杀菌和抗酸二联疗法,随后发展成三联疗法,即铋剂或质子泵抑制剂+2种抗菌药;随着抗菌药物耐药性的增加,开始使用新型钾离子竞争性酸阻断剂沃诺拉赞(VPZ)替代的三联疗法,在克拉霉素耐药率高的地区采用铋四联疗法,但仍难以阻挡根除率下降的趋势.科学家在继续深入研究耐药机制的同时,也在寻找非抗菌药物的策略.益生菌辅助疗法和Hp疫苗有望提高根除率,刺激响应材料也显示出根除Hp的潜力,特别是改变胃液中的氧环境使Hp无法存活的思路为根除提供了新的策略.

Abstract

Helicobacter pylori(Hp)is the causative agent of gastritis and peptic ulcers,and its infection is worldwide,with a high rate of infection.Antimicrobials are ineffective in the acidic environment of the stomach,thus requiring treatments that target both bacteria and stomach acid.Omeprazole and amoxicillin were the classic bactericidal and antacid combination therapy,and then developed into triple therapy,i.e.,bismuth or proton pump inhibitor+2 antimicrobials.With the increase of antimicrobial drug resistance,the triple therapy replaced by the new potassium-competitive acid-blocking agent started to be used,and bismuth quadruple therapy was adopted in areas with high rate of clarithromycin resistance,but it was still difficult to stop the declining trend of the eradication rate.Scientists are searching for strategies with non-antimicrobial drugs while continuing to delve into the mechanisms of resistance.Probiotic-assisted therapies and Hp vaccines are expected to improve eradication rates,and stimuli-responsive materials also show potential for eradicating Hp,especially the idea of altering the oxygen environment in the gastric juice so that Hp cannot survive offers a new strategy for eradication.

关键词

幽门螺杆菌(Hp)/抗菌耐药性/益生菌/疫苗/氧环境

Key words

Helicobacter pylori(Hp)/antimicrobial resistance/probiotic/vaccine/oxygen environment

引用本文复制引用

基金项目

中国博士后科学基金(2022M712556)

出版年

2024
西安交通大学学报(医学版)
西安交通大学

西安交通大学学报(医学版)

CSTPCD北大核心
影响因子:1.144
ISSN:1671-8259
段落导航相关论文